Knowledge Resource Center for Ecological Environment in Arid Area
DOI | 10.1016/j.jpba.2016.11.032 |
Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma | |
Nannetti, Giulio1; Messa, Lorenzo1; Celegato, Marta1; Pagni, Silvana1,2; Basso, Monica1,2; Parisi, Saverio G.1,2; Palu, Giorgio1,2; Loregian, Arianna1,2 | |
通讯作者 | Loregian, Arianna |
来源期刊 | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
![]() |
ISSN | 0731-7085 |
EISSN | 1873-264X |
出版年 | 2017 |
卷号 | 134页码:275-281 |
英文摘要 | Daclatasvir is an inhibitor of hepatitis C virus NS5A protein that is used for the therapy of chronic hepatitis. So far, published methods for analysis of daclatasvir in plasma are exclusively based on mass spectrometry, which is not always available in standard clinical laboratories. Thus, we wished to develop and validate a simple, but still reliable and sensitive high-performance liquid chromatography (HPLC) assay with UV detection for the quantification of daclatasvir, feasible for a wide-spread clinical routine use. The method consisted of solid-phase extraction of daclatasvir using Waters Oasis HLB 1cc cartridges, reversed-phase liquid chromatography with a Waters XTerra RP18 (150 mm x 4.6 mm, 3.5 mu m) column and a mobile phase of ammonium acetate buffer (pH 5.0, 10 mM) and acetonitrile (56:44, v/v), and UV detection at 318 nm. This assay proved to be sensitive (lower limit of quantification of 0.05 mu g/mL), linear (correlation coefficients >= 0.997), specific (no interference with various potentially co-administrated drugs), reproducible (both intra-day and inter-day coefficients of variation <8.9%), and accurate (deviations ranged from -2.2 to 8.0% and from -6.5 to 9.2% for intra-day and inter-day assays, respectively). The method was applied to therapeutic monitoring of patients undergoing daclatasvir therapy for hepatitis C and showed to be reliable and robust. Thus, this method provides a simple, sensitive, precise, and reproducible assay for dosing daclatasvir that can be readily adaptable to routine use by clinical laboratories with standard equipment. In addition, the stability of daclatasvir in plasma was evaluated under various conditions, including after the heating procedure required for inactivation of infectious viruses and in different light exposure conditions. These studies evidenced photo-instability of the compound under sunlight exposure over time. Thus, blood sampling and the whole handling procedure have to be performed quickly and with minimal light exposure. (C) 2016 Elsevier B.V. All rights reserved. |
英文关键词 | Daclatasvir BMS-790052 HCV NS5A inhibitor Solid-phase extraction HPLC-UV Therapeutic drug monitoring |
类型 | Article |
语种 | 英语 |
国家 | Italy |
收录类别 | SCI-E |
WOS记录号 | WOS:000392909900035 |
WOS关键词 | REPLICATION COMPLEX INHIBITOR ; PERFORMANCE LIQUID-CHROMATOGRAPHY ; MASS-SPECTROMETRY METHOD ; QUANTITATIVE-DETERMINATION ; MS/MS METHOD ; BMS-790052 ; RIBAVIRIN ; HIV ; ANTIVIRALS ; ATAZANAVIR |
WOS类目 | Chemistry, Analytical ; Pharmacology & Pharmacy |
WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
资源类型 | 期刊论文 |
条目标识符 | http://119.78.100.177/qdio/handle/2XILL650/200722 |
作者单位 | 1.Univ Padua, Dept Mol Med, Via Gabelli 63, I-35121 Padua, Italy; 2.Padua Univ Hosp, Clin Microbiol & Virol Unit, Padua, Italy |
推荐引用方式 GB/T 7714 | Nannetti, Giulio,Messa, Lorenzo,Celegato, Marta,et al. Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma[J],2017,134:275-281. |
APA | Nannetti, Giulio.,Messa, Lorenzo.,Celegato, Marta.,Pagni, Silvana.,Basso, Monica.,...&Loregian, Arianna.(2017).Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma.JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,134,275-281. |
MLA | Nannetti, Giulio,et al."Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma".JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 134(2017):275-281. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。